Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025

LONDON, Dec. 5, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/5228682

The search for better minimal invasive diagnostic procedures to aid regular monitoring of the patient's response towards the treatment gave birth to liquid biopsy tests. In the recent years, the impressive research on cancer biomarkers' presence in biological fluids, such as blood, which can be collected through minimal invasive techniques has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsies.

Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the patient suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.

The liquid biopsy market is expected to grow at a near double digit annual growth rate. The abilities of liquid biopsy, such as minimal invasiveness, possibility of continuous monitoring of the patient's response towards treatment, and the monitoring of clonal mutations, combined with the growing prominence for precision medicine have fueled the growth of the liquid biopsy market.

The research study comprises in-depth analysis of the market trends and market size through different approaches. The entire market has been segmented and estimated in five different approaches, namely "by product & services", "by biomarker and technology", "by cancer type", "by end users", and "by geography".

In terms of "by products & services", the market has been segmented into kits & reagents, platforms & instruments, and services. In terms of "by biomarker and technology" the market has been segmented into circulating tumor cell (CTC), circulating tumor DNA (ctDNA), and extracellular vesicles (EV). In terms of "by cancer type" the market has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. In terms of "by end users" the market has been tracked through hospital & laboratory, government & academic research centers. And in terms of "by geography" the market has been segmented into North America, Europe, Asia Pacific, and LAMEA.

Some of the key players who have been contributing significantly to the liquid biopsy market are Janssen Diagnostics, LLC; Biocept Inc., Bio-Rad Laboratories Inc., Guardant Health, Inc., Myriad Genetics, QIAGEN, RainDance Technologies, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Natera, Inc., Cynvenio Biosystems, Inc., Epic Sciences, ANGLE plc, Illumina, Inc., Menarini Silicon Biosystems., MDxHealth, Sysmex Inostics GmbH, Genomic Health, and NeoGenomics Laboratories, Inc.

The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering into the global liquid biopsy market.

The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
• How did the liquid biopsy market evolve and what is its scope in the future?
• What are the key developmental strategies which are being implemented by the key players to stand out in this market?
• What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global liquid biopsy market?
• What is the market share of the leading segments and sub-segments of the liquid biopsy market in 2016 and 2025?
• How will each segment of the global liquid biopsy market grow during the forecast period and what will be their revenue generation at the end of 2025?
• Who are the key players dominating the global liquid biopsy market and their respective share?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016-2025?
• Which product type is dominating the market?
• What are the dominating products offered by different companies for each product type, available in the market?
• How the market is distributed on the basis of application?
• Which cancer type is the leading contributor to the global liquid biopsy market revenue?
• Which geographical location will contribute to the highest sales of the liquid biopsy products?

This research report aims at answering various aspects of the global liquid biopsy market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global liquid biopsy market and assesses the factors governing the same.

Executive Summary
A biopsy is the most common, definitive medical procedure used for cancer diagnosis and treatment monitoring. Tissue biopsy is the most widely adopted procedure to diagnose cancer. However, a major drawback of the tissue based diagnosis approach is its dependency on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too.

The search for better minimally invasive diagnostic procedures to aid the regular monitoring of the patient's response towards the treatment, have paved pathway for the most awaited change in diagnostic procedures. In the recent years, the impressive research on cancer biomarkers' presence in biological fluids, such as blood, which can be collected through minimally invasive techniques has opened up new hopes to develop promising minimally invasive diagnostic procedures. These procedures developed based on the detection of biomarkers in biological fluids which were later named as Liquid biopsy.

Liquid biopsy is a non-invasive medical procedure which has the ability to detect the presence of molecular cancer biomarkers in biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the cancer patients.

The purpose of the study is to gain a holistic view of the liquid biopsy market in terms of various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the liquid biopsy market. The global liquid biopsy market has been segmented into five different parts, namely by product, by type of biomarker and technology, by application, by end user, and by geography. These segments have been further segmented into many sub segments to ease the market estimation and to gain a holistic view of the market.

The global liquid biopsy market is anticipated to grow over $4,434 million by 2025. With the growing prominence for non-invasive diagnostic procedures, the global liquid biopsy market is expected to register an impressive double digit growth rate in the forecast period 2016-2025. The global liquid biopsy market, by product, is being dominated by Kits & Consumables, the sub segment was reported to contribute approximately 63% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating share and is estimated to contribute approximately 61% to the global liquid biopsy market value in 2025.

On the other hand, the global liquid biopsy market, by type of biomarker, is being dominated by Circulating Tumor Cells (CTCs), the sub segment was reported to contribute 56% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating market share and is estimated to contribute approximately 45% to the global liquid biopsy market value in 2025.

Additionally, the global liquid biopsy market, by application, is being dominated by Oncology Application. The sub segment was estimated to contribute 97% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its leading share and is estimated to contribute approximately 92% to the global liquid biopsy market value in 2025. The North America liquid biopsy market held the largest market share in 2016. The Asia Pacific liquid biopsy market is expected to register the highest CAGR of 26.3% in the forecast period 2016-2025.

The key players of the market include Adaptive Biotechnologies, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Cynvenio Biosystems, Inc., Epic Sciences, F. Hoffmann-La Roche AG, Genomic Health, Guardant Health, Inc., Illumina, Inc., Janssen Diagnostics, LLC, MDxHealth, Menarini Silicon Biosystems., Myriad Genetics, Natera, Inc., NeoGenomics Laboratories, Inc., QIAGEN, RainDance Technologies, Inc., Sysmex Inostics GmbH, Thermo Fisher Scientific, and Trovagene Inc.

Currently, a significant work is being carried out to develop medical procedure based on liquid biopsy, for diagnosis of several diseases other than cancer. Through the detection of different biomarkers, the diagnosis of cardiovascular diseases, infections, immunological and genetic disorders is certainly possible and opens new hopes for the patients. The development of test kits to diagnose the above mentioned diseases appears to be a great opportunity to serve the market, for both the new and the existing players.

Countries Covered
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Row

Download the full report: https://www.reportbuyer.com/product/5228682

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com